Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. 

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France

     GENTAUR France SARL
    9, rue Lagrange, 75005 Paris 
    Tel 01 43 25 01 50 
    Fax 01 43 25 01 60
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Germany

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA

    usa-flagGenprice Inc, Logistics
    547, Yurok Circle
    San Jose, CA 95123
    Phone/Fax: 

    (408) 780-0908 

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    skype chat

    GENPRICE Inc. invoicing/ accounting:
    6017 Snell Ave, Suite 357
    San Jose, CA. 96123

     

    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    liver-02-polyclonal-peptide-biological-research-productsIncitement of tumor cells devours itself would probably be one of the best decision on the treatment of large numbers of tumor diseases.

    In a new study, researchers found that a combination of certain medications can cause the cancer cells to "cannibalism", without damaging healthy tissue. This type of treatment has demonstrated efficacy in tumors in the colon, liver, lung, breast, brain and kidneys.

    Researchers are trying to determine whether co-administration of drugs sorafenib and regorafenib can be combined with so-called PI3K/AKT inhibitors to achieve better effect.

    Andrew Poklepovic who is co-author of this work, says that despite the need for further research, the results so far are promising. Scientists are encouraged by the fact that the drugs used have already been approved by the FDA to treat certain types of tumors or are currently undergoing trials and pending approval.

    The medicaments sorafenib and regorafenib influence the growth of tumor cells by blocking the release of enzymes - kinases that play a decisive role in the spread of cancer cells.

    Newfound combination drugs enhances this effect, as it adds a new class of kinases inhobitori - PI3K/AKT inhibitors. Thus, many of the tumor cells "starve", limiting tumor growth.

    Published in News

    4950664-3x2-940x627-neural-stem-cells-rat-models-gene-targeting-rosa26-feeder-cells-human-primary-cellsModern technology will allow you to avoid repetitive operations to remove the rest of the tumor.

    Inventors at the University of Western Australia presented the world's smallest portable microscope. It is adapted for the detection of cancerous cells, showing the three-dimensional images. The basic element of the invention is a lens, whose width is one-third of a millimeter, and so it easily fits into the needle.

    Currently new technology passes tests on samples of human tissue. A successful will allow you to avoid repetitive operations to remove the rest of the tumor. According to statistics, nearly one in four women, operated by breast cancer undergoes re-intervention.

    The microscope is set to be used during the operation, which will help to be examined within the tumor. It will also be possible to examine the operation of the lungs in emphysema and cancer of the brain. If the tests pass, the advanced technology could hit the market over the next ten years.

    Published in News
    Tuesday, 16 July 2013 12:02

    Virus against tumor - who will win?

    myxoma-virus-rabbit-knockin-knock-out-mouse-ratWith the combination of myxoma virus and medications that suppress the immune system, it is possible to beat Glioblastoma multiforme - the most common and most lethal form of brain tumor, known to medicine.

    According to Dr. Peter Forsythe from the Center for Cancer Research "Moffitt" this therapy is effective even in the stage of the disease that many physicians would accept for the terminal. Another big plus of successful research is that the new treatment removes one of the most serious obstacles exist to date in the treatment of brain cancer: resistance to temozolomide.

    The new therapy is seen as a "target" for the oncolytic virus invades and destroys only the cancer cells, while chemotherapy affect any tissue of the patient. Myxoma virus that causes virulent diseases in rabbits will be used together with the immunosuppressant rapamycin.

    The precise mechanism by which rapamycin affects the infectious process in tumor cells is not yet well understood, but it is certainly effective - application in laboratory tests contribute to the destruction of more than 89% of the tumor cells by the virus.

    Therapy is now a candidate for clinical trials in humans, but the members of the research group carried out the study were confident of success. Florida State University, Texas, Calgary and the Center for Cancer Research of Ottawa devoted his most brilliant oncologists who are on track to achieve a revolution in the treatment of brain cancer.

    Buy Myxoma products from Gentaur

    Published in News

    In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options. Pancreatic cancer kills nearly 38,000 Americans annually, making it a leading cause of cancer death. The life expectancy for most people diagnosed with it is less than a year.

    Now new research reveals a possible chink in the armor of this recalcitrant disease. Many cancers, including pancreatic, lung, and colon cancer, feature a mutated protein known as Ras that plays a central role in a complex molecular chain of events that drives cancer cell growth and proliferation. It is well known that Ras cancer cells have special nutrient requirements to grow and survive. But how Ras cells cope to actually meet their extraordinary nutrient requirements has been poorly understood—until now. In the study, led by Cosimo Commisso, a postdoctoral fellow in the Department of Biochemistry and Molecular Pharmacology at NYU School of Medicine, show for the first time how Ras cancer cells exploit a process called macropinocytosis to swallow up the protein albumin, which cells then harvest for amino acids essential for growth.

    "A big mystery is how certain tumors meet their excessive nutrient demands ," says Dr. Commisso, whose work is funded in part by the Pancreatic Cancer Action Network. "We believe they accomplish this by macropinocytosis."

    The findings suggest that Ras cancer cells are particularly dependent on macropinocytosis for growth and survival. When the researchers used a chemical to block the uptake of albumin via macropinocytosis in mice with pancreatic tumors, the tumors stopped growing and in some cases even shrank. Moreover, pancreatic cancer cells in mice featured more macropinosomes—the vesicles that transport nutrients deep into a cell—than normal mouse cells.

    The discovery of a "protein eating" mechanism unique to some cancer cells sets the stage for drugs that could block the engulfing process without causing collateral damage to healthy cells and suggests new ways to ferry chemotherapeutic cargo into the heart of cancer cells.

    "This work offers up a completely different way to target cancer metabolism," says lead principal investigator of the study Dafna Bar-Sagi, PhD, senior vice president and vice dean for Science, chief scientific officer and professor, Department of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center, who first identified macropinocytosis in Ras-transformed cancer cells. "It's exciting to think that we can cause the demise of some cancer cells simply by blocking this nutrient delivery process."

    Crucial to the team's findings is the work of Matthew G. Vander Heiden, assistant professor of biology at the David H. Koch Institute for Integrative Cancer Research at MIT and Christian Metallo, assistant professor of bioengineering at the University of California at San Diego, who characterized how Ras cells derive energy from the constituent amino acids released after protein engulfment.

    Other key contributors include Craig B. Thompson, president and CEO of the Memorial Sloan-Kettering Cancer Center and Joshua D. Rabinowitz, professor of chemistry at the Lewis Sigler Institute for Integrative Genomics at Princeton University.

    Published in News

    clinical trails dna rna monoclonal antibody targattMedicine for the treatment of cancer based on a virus destroying tumor cells for the first time successfully passed clinical trials in advanced stage, said U.S. pharmaceutical manufacturer Amgen.

    A statement from the company product has achieved the main objective of the Phase III clinical trial in patients with advanced melanoma - the most aggressive type of skin cancer. The results showed that 16% of patients who received treatment had a significant tumor poured lasting six months or more, compared with only 2% of the control group.

    A spokesman for the company declined to say whether the company will apply for registration to the FDA on the basis of this study.

    It contains the virus Talimogene laherparepvec, genetically modified in a way that causes him to multiply only in rapidly growing cells. The product is injected directly into the tumor, after which the virus enters the cancer cells and causes them to synthesize large amounts of granulocyte-monocyte colony stimulating factor - the hormone that stimulates the maturation of immune cells. When cancerous cells die, they release new amounts of virus and acquired therein colony stimulating factor, which boost the immune system.

    The study was conducted in 400 patients, two thirds of whom received injections every two weeks. The rest of the participants received injections only granulocyte-monocyte colony stimulating factor. According to Dr. Anthony Ribas, melanoma specialist at the University of Los Angeles, the study results are positive, but it is uncertain whether sufficient authorization for use.

    Published in News